https://www.pharmaradar360.com/article/notifiable-diseases-causative-agents-reports-for-2026-32900b46450305d4Pharma Surgeen2026-07-29T15:17:14.000ZNotifiable diseases: causative agents reports for 2026https://www.pharmaradar360.com/article/opinion-the-u-s-could-become-dependent-on-china-for-life-saving-drugs-b0c2402ef42da1bcPharma Surgeen2026-07-29T15:05:27.000ZOpinion | The U.S. could become dependent on China for life-saving drugshttps://www.pharmaradar360.com/article/merck-announces-fourth-quarter-2026-dividend-50947ea895407a1ePharma Surgeen2026-07-29T15:04:00.000ZMerck Announces Fourth-Quarter 2026 Dividendhttps://www.pharmaradar360.com/article/pharma-packaging-jobs-to-grow-5-4-through-2034-b9bbff2bf53b410ePharma Surgeen2026-07-29T15:00:00.000ZPharma Packaging Jobs to Grow 5.4% Through 2034https://www.pharmaradar360.com/article/seventeen-peptide-guidance-revised-what-developers-need-to-know-b00e81c2c02dd747Pharma Surgeen2026-07-29T14:58:39.000ZSeventeen Peptide Guidance Revised: What Developers Need to Knowhttps://www.pharmaradar360.com/article/fda-regenerative-medicine-approvals-show-growing-momentum-2637f03545716749Pharma Surgeen2026-07-29T14:55:43.000ZFDA regenerative medicine approvals show growing momentumhttps://www.pharmaradar360.com/article/moleculin-biotech-files-registration-statement-for-public-offering-shares-fall-acb745e917175c5aPharma Surgeen2026-07-29T14:45:49.000ZMoleculin Biotech Files Registration Statement for Public Offering; Shares Fallhttps://www.pharmaradar360.com/article/why-biotech-is-outpacing-the-ai-slump-3-stocks-to-watch-2026-07-29-investing-new-ef798d58fdd398a3Pharma Surgeen2026-07-29T14:45:00.000ZWhy biotech is outpacing the AI slump: 3 stocks to watch | 2026-07-29 | Investing Newshttps://www.pharmaradar360.com/article/gsk-eyes-future-growth-with-cost-cutting-plan-amid-promising-q2-b076e1774dd228e4Pharma Surgeen2026-07-29T14:40:43.000ZGSK eyes future growth with cost-cutting plan amid promising Q2https://www.pharmaradar360.com/article/where-do-we-stand-on-pharmaceutical-tariffs-431df8cda15fc67dPharma Surgeen2026-07-29T14:38:37.000ZWhere do we stand on pharmaceutical tariffs?https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-nyse-teva-trading-8-2-higher-after-analyst-upgrad-59d570920d199dfePharma Surgeen2026-07-29T14:31:50.000ZTeva Pharmaceutical Industries (NYSE:TEVA) Trading 8.2% Higher After Analyst Upgradehttps://www.pharmaradar360.com/article/novo-nordisk-fails-to-dismiss-lawsuit-over-cagrisema-readout-a5796bc22082c43ePharma Surgeen2026-07-29T14:30:05.000ZNovo Nordisk fails to dismiss lawsuit over CagriSema readouthttps://www.pharmaradar360.com/article/ftre-raised-full-year-guidance-after-strong-biotech-driven-bookings-and-improved-a833c101c7dce7bcPharma Surgeen2026-07-29T14:24:52.000ZFTRE: Raised full-year guidance after strong biotech-driven bookings and improved operational efficiencyhttps://www.pharmaradar360.com/article/the-biotech-growth-trust-plc-net-asset-value-s-b87159afbab2a964Pharma Surgeen2026-07-29T14:11:00.000ZThe Biotech Growth Trust PLC - Net Asset Value(s)https://www.pharmaradar360.com/article/capricor-therapeutics-announces-lancet-publication-of-positive-phase-3-hope-3-tr-f13eb2ed748a3c64Pharma Surgeen2026-07-29T14:10:00.000ZCapricor Therapeutics Announces Lancet Publication of Positive Phase 3 HOPE-3 Trial Results for Deramiocel in Duchenne Muscular Dystrophyhttps://www.pharmaradar360.com/article/atea-pharmaceuticals-achieves-phase-3-success-in-hepatitis-c-trial-5426bac590308403Pharma Surgeen2026-07-29T14:06:43.000ZAtea Pharmaceuticals Achieves Phase 3 Success in Hepatitis C Trialhttps://www.pharmaradar360.com/article/china-biotech-sector-fears-policy-backlash-after-girl-dies-in-gene-editing-trial-35690fe3bfa88260Pharma Surgeen2026-07-29T14:00:14.000ZChina biotech sector fears policy backlash after girl dies in gene-editing trialhttps://www.pharmaradar360.com/article/healthy-planet-healthy-people-the-innovative-pharmaceutical-industry-s-contribut-b38b6b4fbd70432fPharma Surgeen2026-07-29T13:52:30.000ZHealthy planet, healthy people: The innovative pharmaceutical industry's contribution to the Kunming-Montreal Global Biodiversity Frameworkhttps://www.pharmaradar360.com/article/transcript-teva-pharmaceutical-industries-limited-q2-2026-earnings-call-jul-29-2-59f3e641d158f596Pharma Surgeen2026-07-29T13:50:20.000ZTranscript : Teva Pharmaceutical Industries Limited, Q2 2026 Earnings Call, Jul 29, 2026https://www.pharmaradar360.com/article/pcsa-stock-for-stock-acquisition-and-200m-pipe-create-a-btk-focused-biotech-with-7a25614b6d4087a0Pharma Surgeen2026-07-29T13:44:55.000ZPCSA: Stock-for-stock acquisition and $200M PIPE create a BTK-focused biotech with runway into 2029https://www.pharmaradar360.com/article/nhs-england-seeking-provider-for-pharmacy-technician-clinical-training-0577b1db8f6396f3Pharma Surgeen2026-07-29T13:39:09.000ZNHS England seeking provider for pharmacy technician clinical traininghttps://www.pharmaradar360.com/article/pharmalittle-we-re-reading-about-a-fugitive-who-became-a-biotech-exec-a-hospital-c2f070227193af12Pharma Surgeen2026-07-29T13:38:25.000ZPharmalittle: We're reading about a fugitive who became a biotech exec, a hospital suing Lilly, and morehttps://www.pharmaradar360.com/article/state-street-vs-first-trust-is-a-broad-healthcare-or-biotech-focus-better-for-yo-36319f4b3a232225Pharma Surgeen2026-07-29T13:32:55.000ZState Street vs. First Trust: Is a Broad Healthcare or Biotech Focus Better for Your Portfolio?https://www.pharmaradar360.com/article/killing-slime-an-ai-first-biotech-solution-419199dc38c4c60bPharma Surgeen2026-07-29T13:30:38.000ZKilling slime: an AI-first biotech solutionhttps://www.pharmaradar360.com/article/callan-jmb-and-alabama-state-university-break-ground-on-atlas-complex-launching-2f71ebfc71305898Pharma Surgeen2026-07-29T13:26:06.000ZCallan JMB and Alabama State University Break Ground on Atlas Complex, Launching an Unprecedented Strategic Partnership to Advance U.S. Pharmaceutical Manufacturing and Supply Chain Resiliencehttps://www.pharmaradar360.com/article/mid-year-check-in-how-direct-to-patient-momentum-is-accelerating-113d44a55a383f26Pharma Surgeen2026-07-29T13:01:18.000ZMid-Year Check-In: How Direct-to-Patient Momentum Is Acceleratinghttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-vaccine-vgd-template-16eda7af24013a7ePharma Surgeen2026-07-29T13:00:04.000ZRespiratory Syncytial Virus (RSV) vaccine: VGD templatehttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-vaccine-pgd-template-eb0199df34763a87Pharma Surgeen2026-07-29T13:00:04.000ZRespiratory Syncytial Virus (RSV) vaccine: PGD templatehttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-vaccination-programme-7a9417a4fdf76e56Pharma Surgeen2026-07-29T13:00:04.000ZRespiratory syncytial virus (RSV) vaccination programmehttps://www.pharmaradar360.com/article/immunisation-patient-group-direction-pgd-templates-1af7ede7c1c283c6Pharma Surgeen2026-07-29T13:00:04.000ZImmunisation patient group direction (PGD) templateshttps://www.pharmaradar360.com/article/fda-clears-medicus-to-start-gorlin-syndrome-drug-study-04b6f1bfa2357f4fPharma Surgeen2026-07-29T13:00:00.000ZFDA Clears Medicus to Start Gorlin Syndrome Drug Studyhttps://www.pharmaradar360.com/article/reverse-mergers-are-increasingly-popular-caldera-hops-on-synlogic-s-nasdaq-listi-09e14fd75e899e08Pharma Surgeen2026-07-29T12:56:37.000Z‘Reverse mergers are increasingly popular’: Caldera hops on Synlogic’s Nasdaq listinghttps://www.pharmaradar360.com/article/vaccine-update-30d4e36f5ec7eb5aPharma Surgeen2026-07-29T12:37:11.000ZVaccine updatehttps://www.pharmaradar360.com/article/splash-beverage-group-expands-cannepil-platform-into-6bb8018c32594cc9Pharma Surgeen2026-07-29T12:30:00.000ZSplash Beverage Group Expands CannEpil® Platform intohttps://www.pharmaradar360.com/article/lb-pharmaceuticals-announces-150-million-private-placement-702702c95a43501bPharma Surgeen2026-07-29T12:22:46.000ZLB Pharmaceuticals Announces $150 Million Private Placementhttps://www.pharmaradar360.com/article/gerresheimer-sells-centor-and-primary-packaging-plastics-business-for-around-1-5-830ea0d29841de70Pharma Surgeen2026-07-29T12:19:29.000ZGerresheimer Sells Centor And Primary Packaging Plastics Business For Around €1.5 Billionhttps://www.pharmaradar360.com/article/brain-biotech-ag-appoints-dr-sven-k-weber-as-new-chairman-of-the-executive-board-df84e5f98732b2ccPharma Surgeen2026-07-29T12:19:04.000ZBRAIN Biotech AG Appoints Dr. Sven K. Weber as New Chairman of the Executive Board, Effective October 1, 2026https://www.pharmaradar360.com/article/teva-pharmaceutical-industries-nyse-teva-issues-fy-2026-earnings-guidance-f97b00f77d228828Pharma Surgeen2026-07-29T12:13:55.000ZTeva Pharmaceutical Industries (NYSE:TEVA) Issues FY 2026 Earnings Guidancehttps://www.pharmaradar360.com/article/easy-read-guide-to-the-mmrv-vaccination-02488ed69de507a8Pharma Surgeen2026-07-29T12:09:14.000ZEasy read guide to the MMRV vaccinationhttps://www.pharmaradar360.com/article/menb-vaccination-programme-eligible-residential-further-education-settings-ea1c926b97083608Pharma Surgeen2026-07-29T12:06:19.000ZMenB vaccination programme: eligible residential further education settingshttps://www.pharmaradar360.com/article/watch-out-eli-lilly-and-novo-nordisk-amgen-s-monthly-weight-loss-drug-has-6-phas-bae32f27c17dc785Pharma Surgeen2026-07-29T12:04:39.000ZWatch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patientshttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-releases-q2-2026-financial-results-38e74857f649a03aPharma Surgeen2026-07-29T12:04:18.000ZTeva Pharmaceutical Industries Releases Q2 2026 Financial Resultshttps://www.pharmaradar360.com/article/ai-accelerated-nonclinical-drug-testing-market-global-industry-analysis-and-oppo-75b61692d2b3209ePharma Surgeen2026-07-29T12:02:32.000ZAI-Accelerated Nonclinical Drug Testing Market : Global Industry Analysis and Opportunity Assessment, 2036https://www.pharmaradar360.com/article/3-biotech-stocks-with-massive-upside-to-buy-before-august-starts-ee43c1cc3a37dfbcPharma Surgeen2026-07-29T12:00:17.000Z3 Biotech Stocks With Massive Upside to Buy Before August Startshttps://www.pharmaradar360.com/article/azurion-systems-d225046c99d393bdPharma Surgeen2026-07-29T12:00:00.000ZAzurion Systemshttps://www.pharmaradar360.com/article/pharmather-collaborates-with-craft-health-to-evaluate-craftmake-tm-gmp-ready-pha-8f000be8835e2b36Pharma Surgeen2026-07-29T12:00:00.000ZPharmaTher Collaborates with Craft Health to Evaluate CraftMake(TM) GMP-Ready Pharmaceutical 3D Printing Platform for Personalized Peptideshttps://www.pharmaradar360.com/article/is-teva-pharmaceutical-industries-ltd-teva-facing-challenges-a-02afcb9600cae6b1Pharma Surgeen2026-07-29T11:52:22.000ZIs Teva Pharmaceutical Industries Ltd (TEVA) Facing Challenges Ahttps://www.pharmaradar360.com/article/pcsa-stock-jumps-as-traders-pile-into-biotech-micro-cap-11e328034abcbecbPharma Surgeen2026-07-29T11:47:00.000ZPCSA Stock Jumps As Traders Pile Into Biotech Micro-Caphttps://www.pharmaradar360.com/article/how-collegium-s-quarterly-beat-but-softer-outlook-could-reframe-collegium-pharma-0c42dc855dafb310Pharma Surgeen2026-07-29T11:45:14.000ZHow Collegium's Quarterly Beat but Softer Outlook Could Reframe Collegium Pharmaceutical (COLL) Investorshttps://www.pharmaradar360.com/article/v0281-fampridin-neuraxpharm-10mg-0891c61051503614Pharma Surgeen2026-07-29T11:43:55.000ZΑνάκληση της παρτίδας V0281, του φαρμακευτικού προϊόντος FAMPRIDIN-NEURAXPHARM 10MGhttps://www.pharmaradar360.com/article/teva-teva-pharmaceutical-expects-2026-adjusted-eps-range-1-91-2-11-e276dbb238db778fPharma Surgeen2026-07-29T11:39:41.000Z(TEVA) Teva Pharmaceutical Expects 2026 Adjusted EPS Range $1.91 - $2.11https://www.pharmaradar360.com/article/krystal-biotech-international-expansion-and-a-vibrant-pipeline-nasdaq-krys-12b5c2a3792a3252Pharma Surgeen2026-07-29T11:25:50.000ZKrystal Biotech: International Expansion And A Vibrant Pipeline (NASDAQ:KRYS)https://www.pharmaradar360.com/article/silexion-therapeutics-successfully-initiates-phase-2-3-clinical-trial-of-sil204-1ab84a942c01be07Pharma Surgeen2026-07-29T11:20:55.000ZSilexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Centerhttps://www.pharmaradar360.com/article/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2tm-a-pivotal-59a5851a6c7ceea8Pharma Surgeen2026-07-29T11:20:41.000ZTScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancieshttps://www.pharmaradar360.com/article/struggling-sarepta-therapeutics-appoints-former-abbvie-executive-as-savior-594538e5991bfa89Pharma Surgeen2026-07-29T11:14:37.000ZStruggling Sarepta Therapeutics appoints former AbbVie executive as saviorhttps://www.pharmaradar360.com/article/vaccination-coverage-statistics-england-cover-programme-april-2025-to-march-2026-01c427939f3cd7a6Pharma Surgeen2026-07-29T11:10:16.000ZVaccination coverage statistics, England (COVER programme): April 2025 to March 2026https://www.pharmaradar360.com/article/a-one-time-treatment-for-geographic-atrophy-gains-fda-rmat-status-95e47681f20823e0Pharma Surgeen2026-07-29T11:01:00.000ZA one-time treatment for geographic atrophy gains FDA RMAT statushttps://www.pharmaradar360.com/article/pbs-biotech-joins-organoid-commons-to-accelerate-industrialization-and-scalabili-f27a23a2b51fb292Pharma Surgeen2026-07-29T11:00:00.000ZPBS Biotech Joins Organoid COMMONS to Accelerate Industrialization and Scalability of Human-Relevant Modelshttps://www.pharmaradar360.com/article/survey-of-adult-carers-in-england-2025-to-2026-report-e8ab0027540dea50Pharma Surgeen2026-07-29T10:45:00.000ZSurvey of adult carers in England: 2025 to 2026 reporthttps://www.pharmaradar360.com/article/mutation-in-rice-protein-kinase-leads-to-drought-tolerance-b3df69e96ff2c468Pharma Surgeen2026-07-29T10:42:35.000ZMutation in Rice Protein Kinase Leads to Drought Tolerancehttps://www.pharmaradar360.com/article/ukhsa-spend-over-25-000-2026-a8b4b8d9bbff80c2Pharma Surgeen2026-07-29T10:39:15.000ZUKHSA spend over £25,000: 2026https://www.pharmaradar360.com/article/boston-scientific-announces-results-for-second-quarter-2026-d7bd1b5fc65d504fPharma Surgeen2026-07-29T10:30:00.000ZBoston Scientific announces results for second quarter 2026https://www.pharmaradar360.com/article/field-safety-notices-29-june-to-03-july-2026-baec98f35a228b98Pharma Surgeen2026-07-29T10:12:28.000ZField Safety Notices: 29 June to 03 July 2026https://www.pharmaradar360.com/article/legend-biotech-legn-stock-may-be-cheap-after-ceo-resignation-78c34c82bf2eff18Pharma Surgeen2026-07-29T10:08:12.000ZLegend Biotech (LEGN) Stock May Be Cheap After CEO Resignationhttps://www.pharmaradar360.com/article/june-m-a-recap-three-deals-three-billion-dollar-stories-02b7301895fa715fPharma Surgeen2026-07-29T10:06:54.000ZJune M&A recap: Three deals, three billion-dollar storieshttps://www.pharmaradar360.com/article/why-chinese-biotech-licensing-deals-became-attractive-to-us-investors-9ccbf2a2339710dcPharma Surgeen2026-07-29T10:04:53.000ZWhy Chinese Biotech Licensing Deals Became Attractive to US Investorshttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-maternal-vaccination-coverage-in-england-march-2-30e801b2e4b499e7Pharma Surgeen2026-07-29T10:02:46.000ZRespiratory syncytial virus (RSV) maternal vaccination coverage in England: March 2026https://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-older-adults-vaccination-coverage-in-england-jun-6e405552d2e63be0Pharma Surgeen2026-07-29T10:02:24.000ZRespiratory syncytial virus (RSV) older adults vaccination coverage in England: June 2026https://www.pharmaradar360.com/article/biotech-academy-gets-nearly-500k-for-boston-expansion-location-6b2ff9557e0a315aPharma Surgeen2026-07-29T10:00:00.000ZBiotech academy gets nearly $500k for Boston expansion locationhttps://www.pharmaradar360.com/article/zmiany-tak-ale-w-dialogu-i-likwidujace-bariery-cb528f4591811c94Pharma Surgeen2026-07-29T09:52:48.000ZZmiany tak, ale w dialogu i likwidujące barieryhttps://www.pharmaradar360.com/article/tasrif-pharmaceutical-announces-grant-of-second-u-s-patent-for-humanized-monoclo-048578436fdf4c11Pharma Surgeen2026-07-29T09:38:49.000ZTasrif Pharmaceutical Announces Grant of Second U.S. Patent for Humanized Monoclonal Antibodies Against the Poliovirus Receptor (CD155)https://www.pharmaradar360.com/article/krystal-biotech-profitable-self-funding-and-loaded-with-optionality-nasdaq-krys-0094231ae8befaefPharma Surgeen2026-07-29T09:33:01.000ZKrystal Biotech: Profitable, Self-Funding, And Loaded With Optionality (NASDAQ:KRYS)https://www.pharmaradar360.com/article/tasrif-pharmaceutical-announces-grant-of-second-u-s-patent-for-humanized-monoclo-d3728f1bc0f2976cPharma Surgeen2026-07-29T09:30:00.000ZTasrif Pharmaceutical Announces Grant of Second U.S. Patent for Humanized Monoclonal Antibodies Against the Poliovirus Receptor (CD155)https://www.pharmaradar360.com/article/czechia-looks-to-irish-eu-presidency-to-advance-biotech-act-71a3ed32f6165e1aPharma Surgeen2026-07-29T09:24:49.000ZCzechia looks to Irish EU presidency to advance Biotech Acthttps://www.pharmaradar360.com/article/vaccine-update-issue-373-july-2026-9786b36b1f448990Pharma Surgeen2026-07-29T09:24:10.000ZVaccine update: issue 373, July 2026https://www.pharmaradar360.com/article/pnc-financial-services-group-inc-has-2-88-million-stock-holdings-in-teva-pharmac-fdea3d2fab72c23aPharma Surgeen2026-07-29T09:18:14.000ZPNC Financial Services Group Inc. Has $2.88 Million Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/cabenuva-demonstrates-superiority-to-daily-oral-therapy-in-adolescents-living-wi-8fb606717756e973Pharma Surgeen2026-07-29T09:08:12.000ZCabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026https://www.pharmaradar360.com/article/guidance-digital-mental-health-technology-qualification-and-classification-e2a4c7cf41aed2d8Pharma Surgeen2026-07-29T09:00:07.000ZGuidance: Digital mental health technology: qualification and classificationhttps://www.pharmaradar360.com/article/guidance-ambient-voice-technology-enabled-products-621b64a261993136Pharma Surgeen2026-07-29T09:00:07.000ZGuidance: Ambient voice technology-enabled productshttps://www.pharmaradar360.com/article/is-vr-training-for-pharmaceutical-manufacturing-a-reality-founder-gives-peek-beh-1097b3d6a2bbd61fPharma Surgeen2026-07-29T08:45:53.000ZIs VR training for pharmaceutical manufacturing a reality? — Founder gives peek behind the curtainhttps://www.pharmaradar360.com/article/what-trump-s-200-tariff-threat-on-generics-means-to-pharmaceutical-industry-4ec005321e580e68Pharma Surgeen2026-07-29T08:40:32.000ZWhat Trump’s 200% tariff threat on generics means to pharmaceutical industryhttps://www.pharmaradar360.com/article/novo-pharmatech-ceo-rapid-change-in-the-pharmaceutical-industry-is-placing-new-d-75eb428e92fcd3dePharma Surgeen2026-07-29T08:37:00.000ZNovo Pharmatech CEO: Rapid change in the pharmaceutical industry is placing new demands on managementhttps://www.pharmaradar360.com/article/the-va-could-help-america-win-the-biotechnology-race-with-china-6905c218ebce5341Pharma Surgeen2026-07-29T08:34:35.000ZThe VA could help America win the biotechnology race with Chinahttps://www.pharmaradar360.com/article/in-the-biotech-industry-a-most-wanted-fugitive-was-long-hiding-in-plain-sight-f78b9c8eaa225647Pharma Surgeen2026-07-29T08:33:34.000ZIn the biotech industry, a most-wanted fugitive was long hiding in plain sighthttps://www.pharmaradar360.com/article/communicable-disease-outbreak-management-guidance-01d44b0203a04ae5Pharma Surgeen2026-07-29T08:30:03.000ZCommunicable disease outbreak management guidancehttps://www.pharmaradar360.com/article/8-5d556bb5ea935863Pharma Surgeen2026-07-29T08:30:00.000Z令和8年熊本地震による被害への支援についてhttps://www.pharmaradar360.com/article/support-for-areas-affected-by-the-2026-kumamoto-prefecture-earthquake-e5b7d65746aac4c8Pharma Surgeen2026-07-29T08:30:00.000ZSupport for Areas Affected by the 2026 Kumamoto Prefecture Earthquakehttps://www.pharmaradar360.com/article/la-aemps-concede-los-v-premios-pran-2026-a-nueve-iniciativas-frente-a-la-resiste-1e5e2f380b0c42e3Pharma Surgeen2026-07-29T08:28:47.000ZLa AEMPS concede los V Premios PRAN 2026 a nueve iniciativas frente a la resistencia a los antimicrobianoshttps://www.pharmaradar360.com/article/does-legend-biotech-s-legn-ceo-exit-reshape-confidence-in-its-cell-therapy-expan-45420c677f65b71dPharma Surgeen2026-07-29T08:21:55.000ZDoes Legend Biotech’s (LEGN) CEO Exit Reshape Confidence In Its Cell Therapy Expansion Strategy?https://www.pharmaradar360.com/article/biotech-stocks-at-52-week-highs-incy-rises-with-q2-results-plse-si-bvs-lbrx-3ee03efcad66a19dPharma Surgeen2026-07-29T08:21:00.000ZBiotech Stocks At 52-Week Highs - INCY Rises With Q2 Results, PLSE, SI, BVS, LBRXhttps://www.pharmaradar360.com/article/regulatory-round-up-29-july-2026-41aee1be3460438bPharma Surgeen2026-07-29T08:20:39.000ZRegulatory round-up: 29 July 2026https://www.pharmaradar360.com/article/price-to-sales-forward-of-lushang-freda-pharmaceutical-co-ltd-class-a-sse-600223-81f4314c084d1f07Pharma Surgeen2026-07-29T08:15:50.000ZPrice to sales forward of Lushang Freda Pharmaceutical Co., Ltd. Class A – SSE:600223https://www.pharmaradar360.com/article/rtw-biotech-s-portfolio-company-completes-merger-with-vyne-therapeutics-34a752bee5ede95aPharma Surgeen2026-07-29T08:08:26.000ZRTW Biotech's Portfolio Company Completes Merger with Vyne Therapeuticshttps://www.pharmaradar360.com/article/paradigm-asx-par-reaches-50-enrolment-in-phase-3-osteoarthritis-trial-will-inter-547a288e4a60a102Pharma Surgeen2026-07-29T08:07:00.000ZParadigm (ASX:PAR) Reaches 50% Enrolment in Phase 3 Osteoarthritis Trial - Will Interim Analysis Be Its Defining Moment?https://www.pharmaradar360.com/article/handling-manufacturer-investigation-reports-for-medical-devices-and-ivds-b20515875324179bPharma Surgeen2026-07-29T08:05:30.000ZHandling Manufacturer Investigation Reports for Medical Devices and IVDshttps://www.pharmaradar360.com/article/aids-2026-some-pieces-falling-into-place-for-monthly-hiv-prevention-pill-but-key-97f3e4d173acaeb4Pharma Surgeen2026-07-29T08:03:05.000ZAIDS 2026: Some pieces falling into place for monthly HIV prevention pill, but key data not yet inhttps://www.pharmaradar360.com/article/mumbai-s-elite-clubs-under-scanner-fda-suspends-food-licences-of-five-iconic-clu-7d07ee33109e1f06Pharma Surgeen2026-07-29T07:46:00.000ZMumbai's elite clubs under scanner: FDA suspends food licences of five iconic clubs over serious hygiene violationshttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-teva-shares-purchased-by-adar1-capital-manage-5aee996cfb611dbbPharma Surgeen2026-07-29T07:18:08.000ZTeva Pharmaceutical Industries Ltd. $TEVA Shares Purchased by ADAR1 Capital Management LLChttps://www.pharmaradar360.com/article/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-tre-19edeb0428ff1b00Pharma Surgeen2026-07-29T07:00:00.000ZAbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areatahttps://www.pharmaradar360.com/article/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-tre-3f613233d05ea555Pharma Surgeen2026-07-29T07:00:00.000ZAbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligohttps://www.pharmaradar360.com/article/12-funding-rounds-that-show-where-apac-biotech-capital-is-going-dbbb6ea00ab42674Pharma Surgeen2026-07-29T06:57:42.000Z12 Funding Rounds That Show Where APAC Biotech Capital Is Goinghttps://www.pharmaradar360.com/article/atea-s-bemnifosbuvir-ruzasvir-meets-endpoints-in-phase-3-hepatitis-c-trial-5223bcf3ea5be180Pharma Surgeen2026-07-29T06:51:08.000ZAtea’s Bemnifosbuvir/Ruzasvir Meets Endpoints in Phase 3 Hepatitis C Trialhttps://www.pharmaradar360.com/article/long-covid-s-phase-3-reckoning-what-stimulate-icp-reveals-about-designing-trials-7dcf7c832a7ac3bfPharma Surgeen2026-07-29T06:51:08.000ZLong COVID’s Phase 3 Reckoning: What STIMULATE-ICP Reveals About Designing Trials for Diseases Medicine Can’t Yet Explainhttps://www.pharmaradar360.com/article/bacchus-sales-lift-dong-a-socio-holdings-to-record-q2-revenue-f7de227534d9ab2dPharma Surgeen2026-07-29T06:10:30.000ZBacchus sales lift Dong-A Socio Holdings to record Q2 revenuehttps://www.pharmaradar360.com/article/ingenia-therapeutics-sets-ipo-price-at-12-000-9934ccd0238344c0Pharma Surgeen2026-07-29T06:09:34.000ZIngenia Therapeutics sets IPO price at ₩12,000https://www.pharmaradar360.com/article/hanmi-pharm-s-q2-operating-profit-doubles-on-rosuzet-growth-eli-lilly-licensing-e55257d0456adc0dPharma Surgeen2026-07-29T06:09:26.000ZHanmi Pharm's Q2 operating profit doubles on Rosuzet growth, Eli Lilly licensing dealhttps://www.pharmaradar360.com/article/legend-biotech-legn-ceo-exit-tests-management-stability-around-its-car-t-multipl-3de2f469bfb75830Pharma Surgeen2026-07-29T06:08:00.000ZLegend Biotech (LEGN) CEO Exit Tests Management Stability Around Its CAR-T Multiple Myeloma Strategyhttps://www.pharmaradar360.com/article/aids-activists-slam-pharmaceutical-companies-greed-over-hiv-drug-2b95cb75891c88cbPharma Surgeen2026-07-29T06:05:26.000ZAIDS activists slam pharmaceutical companies’ greed over HIV drughttps://www.pharmaradar360.com/article/blister-packaging-market-expands-as-pharmaceutical-demand-and-sustainable-innova-a920ec3e09738e9fPharma Surgeen2026-07-29T05:58:00.000ZBlister Packaging Market Expands as Pharmaceutical Demand and Sustainable Innovation Drive Global Growthhttps://www.pharmaradar360.com/article/ingenia-therapeutics-sets-ipo-price-at-12-000-384f6db48841d7d6Pharma Surgeen2026-07-29T05:39:28.000ZIngenia Therapeutics sets IPO price at ₩12,000https://www.pharmaradar360.com/article/top-portage-biotech-alp-competitors-2026-f77a722fc11c05f7Pharma Surgeen2026-07-29T05:27:41.000ZTop Portage Biotech (ALP) Competitors 2026https://www.pharmaradar360.com/article/chugai-pharmaceutical-co-ltd-unsponsored-adr-otcmkts-chgcy-sees-large-growth-in-46ed2f26bb533c45Pharma Surgeen2026-07-29T05:23:42.000ZChugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Sees Large Growth in Short Interesthttps://www.pharmaradar360.com/article/uk-biotech-venture-investment-hits-five-year-high-a46145c699cd4e1fPharma Surgeen2026-07-29T05:03:27.000ZUK biotech venture investment hits five-year highhttps://www.pharmaradar360.com/article/hanmi-pharm-s-q2-operating-profit-doubles-on-rosuzet-growth-eli-lilly-licensing-e3750611cd1685fePharma Surgeen2026-07-29T04:47:37.000ZHanmi Pharm's Q2 operating profit doubles on Rosuzet growth, Eli Lilly licensing dealhttps://www.pharmaradar360.com/article/legend-biotech-legn-replaces-ceo-ying-huang-with-interim-chief-alan-bash-d973ebdfd515ef90Pharma Surgeen2026-07-29T04:27:58.000ZLegend Biotech (LEGN) Replaces CEO Ying Huang With Interim Chief Alan Bashhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-shenyang-xingqi-pharmaceutical-co-ltd-cla-40ce4e7c023a943aPharma Surgeen2026-07-29T03:30:03.000ZEnterprise value to revenue forward of Shenyang Xingqi Pharmaceutical Co., Ltd. Class A – SZSE:300573https://www.pharmaradar360.com/article/fda-suspends-food-licences-of-five-mumbai-clubs-over-hygiene-violations-43f6889b120252ddPharma Surgeen2026-07-29T03:29:30.000ZFDA suspends food licences of five Mumbai clubs over hygiene violationshttps://www.pharmaradar360.com/article/fda-suspends-food-licences-of-five-mumbai-clubs-over-hygiene-violations-ba18fa8b29d56b41Pharma Surgeen2026-07-29T03:25:53.000ZFDA suspends food licences of five Mumbai clubs over hygiene violationshttps://www.pharmaradar360.com/article/mumbai-fda-cracks-down-on-elite-clubs-suspends-fssai-licences-of-cci-mig-cricket-e158b2c4acf98386Pharma Surgeen2026-07-29T02:43:00.000ZMumbai FDA cracks down on elite clubs, suspends FSSAI licences of CCI, MIG Cricket Club, Juhu Gymkhana and othershttps://www.pharmaradar360.com/article/sinovac-biotech-ltd-revenue-breakdown-fwb-svq-c9312febf29466e3Pharma Surgeen2026-07-29T02:06:34.000ZSinovac Biotech Ltd. Revenue Breakdown – FWB:SVQhttps://www.pharmaradar360.com/article/fda-staff-reiterate-concerns-about-replimune-skin-cancer-treatment-f55b472671a2d631Pharma Surgeen2026-07-29T01:36:13.000ZFDA staff reiterate concerns about Replimune skin cancer treatmenthttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-syngen-biotech-co-ltd-tpex-8279-ec02fa2d857ef209Pharma Surgeen2026-07-29T01:25:04.000ZPrice to earnings forward of Syngen Biotech Co., Ltd. – TPEX:8279https://www.pharmaradar360.com/article/price-to-sales-forward-of-syngen-biotech-co-ltd-tpex-8279-21e2fd15c61c97edPharma Surgeen2026-07-29T01:19:57.000ZPrice to sales forward of Syngen Biotech Co., Ltd. – TPEX:8279https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-syngen-biotech-co-ltd-tpex-8279-9cab19deab384b97Pharma Surgeen2026-07-29T00:28:56.000ZEnterprise value to EBIT forward of Syngen Biotech Co., Ltd. – TPEX:8279https://www.pharmaradar360.com/article/price-to-book-forward-of-syngen-biotech-co-ltd-tpex-8279-dbcd929ceb87ad17Pharma Surgeen2026-07-29T00:26:43.000ZPrice to book forward of Syngen Biotech Co., Ltd. – TPEX:8279https://www.pharmaradar360.com/article/nkgen-biotech-inc-revenue-breakdown-otc-nkgnw-2ae6af42c538edddPharma Surgeen2026-07-29T00:16:10.000ZNKGen Biotech Inc. Revenue Breakdown – OTC:NKGNWhttps://www.pharmaradar360.com/article/biogen-filed-form-10-q-ec5d05639bfa25d0Pharma Surgeen2026-07-29T00:00:00.000ZBiogen filed Form 10-Qhttps://www.pharmaradar360.com/article/biogen-filed-form-8-k-e9e52a450c319d08Pharma Surgeen2026-07-29T00:00:00.000ZBiogen filed Form 8-Khttps://www.pharmaradar360.com/article/otsuka-foods-to-launch-micro-magic-french-fries-black-pepper-a-new-flavor-for-ad-8f91c923bf7775faPharma Surgeen2026-07-29T00:00:00.000ZOtsuka Foods to Launch Micro Magic French Fries: Black Pepper A New Flavor for Adults, Microwavable in the Box, Perfect with Drinks In Stores across Japan from August 24, 2026https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-3c204c7d85528a9cPharma Surgeen2026-07-29T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-13fdc9339c701686Pharma Surgeen2026-07-29T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-c447c94ebe01b4fbPharma Surgeen2026-07-29T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-8d340d0f712f2567Pharma Surgeen2026-07-29T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-9207f83803ed11f1Pharma Surgeen2026-07-29T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-e6d51a3b92ad9111Pharma Surgeen2026-07-29T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-c29e138b151ee5a5Pharma Surgeen2026-07-29T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-04e9864f8fa520d4Pharma Surgeen2026-07-29T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-53a75985dd8993adPharma Surgeen2026-07-29T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-0dfc90e247884682Pharma Surgeen2026-07-29T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-e89dfbc94ab736d1Pharma Surgeen2026-07-29T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-d9dc0edb7cf1b326Pharma Surgeen2026-07-29T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-7db4c1040753ae01Pharma Surgeen2026-07-29T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-b3d45a5226db188dPharma Surgeen2026-07-29T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/notice-of-award-of-a-sole-source-cooperative-agreement-to-fund-the-public-health-57d4915d6e170dacPharma Surgeen2026-07-29T00:00:00.000ZNotice of Award of a Sole Source Cooperative Agreement To Fund the Public Health Foundationhttps://www.pharmaradar360.com/article/medical-devices-radiology-devices-classification-of-the-phase-changing-fiducial-4d452b7d356ad019Pharma Surgeen2026-07-29T00:00:00.000ZMedical Devices; Radiology Devices; Classification of the Phase-Changing Fiducial Marker for Radiation Therapyhttps://www.pharmaradar360.com/article/statement-of-organization-functions-and-delegations-of-authority-4d17606b21112b54Pharma Surgeen2026-07-29T00:00:00.000ZStatement of Organization, Functions, and Delegations of Authorityhttps://www.pharmaradar360.com/article/notice-of-diabetes-mellitus-interagency-coordinating-committee-meeting-33eb1556867c5e16Pharma Surgeen2026-07-29T00:00:00.000ZNotice of Diabetes Mellitus Interagency Coordinating Committee Meetinghttps://www.pharmaradar360.com/article/product-specific-guidances-revised-draft-guidances-for-industry-availability-b89b43d521f5fb72Pharma Surgeen2026-07-29T00:00:00.000ZProduct-Specific Guidances; Revised Draft Guidances for Industry; Availabilityhttps://www.pharmaradar360.com/article/privacy-act-of-1974-matching-program-c57b39084bc75bb2Pharma Surgeen2026-07-29T00:00:00.000ZPrivacy Act of 1974; Matching Programhttps://www.pharmaradar360.com/article/drug-label-update-aspercreme-lidocaine-no-mess-plus-lavender-8366bb2b745da40cPharma Surgeen2026-07-29T00:00:00.000ZDrug label update: Aspercreme Lidocaine No-Mess plus Lavenderhttps://www.pharmaradar360.com/article/cleveland-wnba-names-cleveland-clinic-as-third-founding-partner-and-official-hos-8949e35f03df556fPharma Surgeen2026-07-29T00:00:00.000ZCleveland WNBA Names Cleveland Clinic as Third Founding Partner and Official Hospital and Sports Medicine Providerhttps://www.pharmaradar360.com/article/united-therapeutics-corporation-announces-advance-outcomes-study-of-ralinepag-pu-505e7eeba2042bb7Pharma Surgeen2026-07-29T00:00:00.000ZUnited Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancethttps://www.pharmaradar360.com/article/myxedema-coma-despite-mild-biochemical-hypothyroidism-a-case-of-profound-clinica-f7e9d0ecefdf5f3dPharma Surgeen2026-07-29T00:00:00.000ZMyxedema Coma Despite Mild Biochemical Hypothyroidism: A Case of Profound Clinical Decompensationhttps://www.pharmaradar360.com/article/cultural-competence-and-clinical-decision-making-among-nurses-in-the-philippines-049458620489d60fPharma Surgeen2026-07-29T00:00:00.000ZCultural Competence and Clinical Decision-Making among Nurses in the Philippineshttps://www.pharmaradar360.com/article/cross-species-study-of-canine-and-human-peripheral-nerve-sheath-tumors-clinical-1b80a2a8ca002d5cPharma Surgeen2026-07-29T00:00:00.000ZCross-species Study of Canine and Human Peripheral Nerve Sheath Tumors: Clinical and Molecular Perspectiveshttps://www.pharmaradar360.com/article/intravenous-ketamine-for-depressed-and-suicidal-adolescents-in-the-emergency-dep-1865bd09ec9b0288Pharma Surgeen2026-07-29T00:00:00.000ZIntravenous Ketamine for Depressed and Suicidal Adolescents in the Emergency Department: A Randomized Double-Blind Trialhttps://www.pharmaradar360.com/article/clinical-and-pathogenetic-interactions-between-metabolic-dysfunction-associated-8827ed4b48d9ba9bPharma Surgeen2026-07-29T00:00:00.000ZCLINICAL AND PATHOGENETIC INTERACTIONS BETWEEN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE AND INFLAMMATORY BOWEL DISEASES: THE ROLE OF METABOLIC DISORDERS, MICROBIOTA, AND SYSTEMIC INFLAMMATIONhttps://www.pharmaradar360.com/article/clinical-characteristics-antibiotic-resistance-patterns-and-factors-associated-w-7ffcebf9cf77e11aPharma Surgeen2026-07-29T00:00:00.000ZClinical characteristics, antibiotic resistance patterns, and factors associated with mortality in neonatal Serratia marcescens bloodstream infections: a single-center retrospective cohort studyhttps://www.pharmaradar360.com/article/comparative-analgesic-effects-of-lidocaine-dexmedetomidine-co-administration-in-e425720ff4282973Pharma Surgeen2026-07-29T00:00:00.000ZComparative analgesic effects of lidocaine–dexmedetomidine co-administration in major laparoscopic gynecologic surgery: a randomized controlled trialhttps://www.pharmaradar360.com/article/exposure-based-video-therapy-for-obsessive-compulsive-disorder-and-posttraumatic-0d6aee710fdc9ce8Pharma Surgeen2026-07-29T00:00:00.000ZExposure-Based Video Therapy for Obsessive-Compulsive Disorder and Posttraumatic Stress Disorderhttps://www.pharmaradar360.com/article/impact-of-foreign-institutional-investment-on-share-price-and-market-capitalisat-fb7725b542b6db6fPharma Surgeen2026-07-29T00:00:00.000ZImpact of Foreign Institutional Investment on Share Price and Market Capitalisation of Indian Pharmaceutical Companieshttps://www.pharmaradar360.com/article/co-adjuvant-intravenous-corticosteroids-for-septic-arthritis-cicsa-a-proposal-of-f45715534c7b2ca7Pharma Surgeen2026-07-29T00:00:00.000ZCo-Adjuvant Intravenous Corticosteroids for Septic Arthritis (CICSA): A Proposal of a Multicenter Randomized Controlled Trialhttps://www.pharmaradar360.com/article/homozygous-nonsense-dsp-variants-selectively-affecting-desmoplakin-i-cause-carva-8266235127b31bebPharma Surgeen2026-07-29T00:00:00.000ZHomozygous Nonsense DSP Variants Selectively Affecting Desmoplakin I Cause Carvajal Syndrome in a Consanguineous Arabian Family with Four Affected Female Siblingshttps://www.pharmaradar360.com/article/immediate-changes-in-physical-function-psychological-health-and-health-related-q-66b9c53d24a37833Pharma Surgeen2026-07-29T00:00:00.000ZImmediate Changes in Physical Function, Psychological Health, and Health-Related Quality of Life Following a Five-Day Multicomponent Coastal Health Program in Postmenopausal Women: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/analysis-of-clinical-indicators-in-pediatric-patients-with-acinetobacter-baumann-54e393c3ee391b73Pharma Surgeen2026-07-29T00:00:00.000ZAnalysis of Clinical Indicators in Pediatric Patients with Acinetobacter baumannii and Klebsiella pneumoniae Infectionshttps://www.pharmaradar360.com/article/preoperative-thyroid-hormone-ratios-and-complete-blood-count-cbc-derived-biomark-8f9104a12a7f2213Pharma Surgeen2026-07-29T00:00:00.000ZPreoperative Thyroid Hormone Ratios and Complete Blood Count (CBC)-Derived Biomarkers for Differentiating Benign Thyroid Nodules from Papillary Thyroid Carcinoma: A Retrospective Single-Center Case–Control Studyhttps://www.pharmaradar360.com/article/a-history-of-psychiatric-hospitalization-and-surgically-managed-facial-abscess-a-cbb16c30686b1f8ePharma Surgeen2026-07-29T00:00:00.000ZA History of Psychiatric Hospitalization and Surgically Managed Facial Abscess: An Observed-to-Expected Association Analysishttps://www.pharmaradar360.com/article/robotic-assisted-spinal-instrumentation-from-c1-to-s1-experience-of-a-uk-neurosu-48dba15ab61ce7aaPharma Surgeen2026-07-29T00:00:00.000ZRobotic-Assisted Spinal Instrumentation from C1 to S1 Experience of a UK Neurosurgical Tertiary Referral Centrehttps://www.pharmaradar360.com/article/basic-clinical-bidirectional-empowerment-synergistic-breakthrough-in-molecular-m-75ebac08216e6873Pharma Surgeen2026-07-29T00:00:00.000ZBasic Clinical Bidirectional Empowerment: Synergistic Breakthrough in Molecular Mechanisms and Clinical Management of Small Cell Cervical Carcinomahttps://www.pharmaradar360.com/article/refining-the-vision-of-clinical-bioenergetics-updated-aims-and-scope-for-an-evol-111a9d8bd72720b9Pharma Surgeen2026-07-29T00:00:00.000ZRefining the Vision of Clinical Bioenergetics: Updated Aims and Scope for an Evolving Fieldhttps://www.pharmaradar360.com/article/high-in-vitro-activity-of-the-novel-pleuromutilin-antibiotic-lefamulin-on-clinic-d323507093536b8fPharma Surgeen2026-07-29T00:00:00.000ZHigh In Vitro Activity of the Novel Pleuromutilin Antibiotic, Lefamulin, on Clinical Helicobacter pylori Isolateshttps://www.pharmaradar360.com/article/in-vitro-activity-of-imipenem-funobactam-against-clinical-isolates-of-gram-negat-90eb21f2a95a3a08Pharma Surgeen2026-07-29T00:00:00.000ZIn Vitro Activity of Imipenem-Funobactam Against Clinical Isolates of Gram-Negative Bacillihttps://www.pharmaradar360.com/article/axillary-surgical-de-escalation-after-neoadjuvant-therapy-in-breast-cancer-curre-419c0e71ec824455Pharma Surgeen2026-07-29T00:00:00.000ZAxillary surgical de-escalation after neoadjuvant therapy in breast cancer: current evidence, clinical controversies, and future directionshttps://www.pharmaradar360.com/article/a-novel-clinical-perspective-on-subarachnoid-hemorrhage-complicated-by-myocardia-a454aec1fea97d18Pharma Surgeen2026-07-29T00:00:00.000ZA novel clinical perspective on subarachnoid hemorrhage complicated by myocardial injury: independent predictors and short-term prognostic assessmenthttps://www.pharmaradar360.com/article/clinical-determinants-of-survival-outcomes-and-acute-toxicity-after-adoptive-cel-a02bc052df804db3Pharma Surgeen2026-07-29T00:00:00.000ZClinical determinants of survival outcomes and acute toxicity after adoptive cellular therapy for solid tumorshttps://www.pharmaradar360.com/article/educational-attainment-and-drug-firm-innovation-7fd7e99712ca45c0Pharma Surgeen2026-07-29T00:00:00.000ZEducational Attainment and Drug Firm Innovationhttps://www.pharmaradar360.com/article/randomized-clinical-trials-and-real-world-clinical-practice-data-for-hr-positive-7f62efcee29c7679Pharma Surgeen2026-07-29T00:00:00.000ZRandomized clinical trials and real-world clinical practice data for HR positive/HER2 negative metastatic breast cancer: a critical analysis of the evidence base. A reviewhttps://www.pharmaradar360.com/article/mas-alla-del-0-respuesta-mantenida-a-quimioinmunoterapia-en-pd-l1-negativo-e3750f0f79fafb42Pharma Surgeen2026-07-29T00:00:00.000ZMás allá del 0%: respuesta mantenida a quimioinmunoterapia en PD-L1 negativohttps://www.pharmaradar360.com/article/conversational-ai-establishes-patient-understanding-before-clinician-contact-a-r-7d2e8633d736533cPharma Surgeen2026-07-29T00:00:00.000ZConversational AI Establishes Patient Understanding Before Clinician Contact: A Randomized Equivalence Trial (Preprint)https://www.pharmaradar360.com/article/inverted-takotsubo-cardiomyopathy-triggered-by-corticosteroid-administration-in-52613e1af3ce504bPharma Surgeen2026-07-29T00:00:00.000ZInverted Takotsubo Cardiomyopathy Triggered by Corticosteroid Administration in a Patient with Undiagnosed Pheochromocytomahttps://www.pharmaradar360.com/article/association-of-apoe-gene-expression-with-thyroid-dysfunction-inflammation-and-ni-f69204d561ead3a0Pharma Surgeen2026-07-29T00:00:00.000ZAssociation of APOE gene expression with thyroid dysfunction, inflammation, and nitrosative stress in cardiometabolic syndrome: a case–control studyhttps://www.pharmaradar360.com/article/fda-inspection-preparation-4cf19cf940a1e4adPharma Surgeen2026-07-29T00:00:00.000ZFDA Inspection Preparationhttps://www.pharmaradar360.com/article/humanitarian-use-devices-1fb9b0f0dcda8c99Pharma Surgeen2026-07-29T00:00:00.000ZHumanitarian-Use Deviceshttps://www.pharmaradar360.com/article/investigator-site-file-f9d215c9b11e85ecPharma Surgeen2026-07-29T00:00:00.000ZInvestigator Site Filehttps://www.pharmaradar360.com/article/data-management-70140cc7c444e80ePharma Surgeen2026-07-29T00:00:00.000ZData Managementhttps://www.pharmaradar360.com/article/clinical-trials-laws-and-regulations-016e862ee3365403Pharma Surgeen2026-07-29T00:00:00.000ZClinical Trials Laws and Regulationshttps://www.pharmaradar360.com/article/investigational-drug-compounding-vs-manufacturing-ba11523c7ed825b9Pharma Surgeen2026-07-29T00:00:00.000ZInvestigational Drug Compounding vs. Manufacturinghttps://www.pharmaradar360.com/article/medwatch-e7b75e14d904e6e3Pharma Surgeen2026-07-29T00:00:00.000ZMedWatchhttps://www.pharmaradar360.com/article/site-initiation-and-site-initiation-visit-siv-procedures-99a3a81028469d1aPharma Surgeen2026-07-29T00:00:00.000ZSite Initiation and Site Initiation Visit (SIV) Procedureshttps://www.pharmaradar360.com/article/introduction-5b877ac6e06b7d4ePharma Surgeen2026-07-29T00:00:00.000ZIntroductionhttps://www.pharmaradar360.com/article/psychological-outcomes-and-intention-to-use-following-an-8-week-virtual-reality-c726b44f2f4e0540Pharma Surgeen2026-07-29T00:00:00.000ZPsychological outcomes and intention to use following an 8-week virtual reality tennis training programme: a randomised controlled trial with exploratory mediation analysishttps://www.pharmaradar360.com/article/accelerated-biological-aging-mediates-the-associations-of-plasma-lactate-and-the-2488e96c978e7b64Pharma Surgeen2026-07-29T00:00:00.000ZAccelerated biological aging mediates the associations of plasma lactate and the glucose-lactate index with MASLD: a prospective cohort studyhttps://www.pharmaradar360.com/article/multi-omics-analysis-reveals-micb-promotes-cerebral-atherosclerosis-through-ftmt-e953a1c97b6c8e8aPharma Surgeen2026-07-29T00:00:00.000ZMulti-omics analysis reveals MICB promotes cerebral atherosclerosis through FTMT suppression in NK and plasma cellshttps://www.pharmaradar360.com/article/development-and-validation-of-the-analytical-method-for-determination-of-residua-5ad26176e1e527fcPharma Surgeen2026-07-29T00:00:00.000ZDevelopment and validation of the analytical method for determination of residual solvents (2-propanol and n-hexane) in the drug substance Inosine Pranobexhttps://www.pharmaradar360.com/article/construction-of-a-comprehensive-competency-evaluation-index-system-for-clinical-3738af9bde37991ePharma Surgeen2026-07-29T00:00:00.000ZConstruction of a comprehensive competency evaluation index system for clinical nursing instructors based on a multifaceted feedback modelhttps://www.pharmaradar360.com/article/prenatal-ultrasound-findings-associated-with-intrauterine-cmv-infection-a-multic-c29fe4deb071723bPharma Surgeen2026-07-29T00:00:00.000ZPrenatal ultrasound findings associated with intrauterine CMV infection: a multicenter retrospective analysis of clinical and sonographic featureshttps://www.pharmaradar360.com/article/novel-blood-lncrna-biomarkers-associated-with-clinical-severity-and-specific-cog-04f02304a8d2d797Pharma Surgeen2026-07-29T00:00:00.000ZNovel blood lncRNA biomarkers associated with clinical severity and specific cognitive dimensions in Alzheimer's diseasehttps://www.pharmaradar360.com/article/global-regional-and-national-burden-of-major-depressive-disorder-from-1990-to-20-eb82129583ca6b92Pharma Surgeen2026-07-29T00:00:00.000ZGlobal, Regional, and National Burden of Major Depressive Disorder From 1990 to 2021: Analysis of Data From GBD 2021https://www.pharmaradar360.com/article/oral-semaglutide-for-alcohol-use-disorder-a-randomized-clinical-trial-43bbd17e7a24e536Pharma Surgeen2026-07-29T00:00:00.000ZOral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trialhttps://www.pharmaradar360.com/article/supplementary-table-s10-from-clinical-validation-of-tissue-and-liquid-companion-568bd8ffa66aec0ePharma Surgeen2026-07-29T00:00:00.000ZSupplementary Table S10 from Clinical Validation of Tissue and Liquid Companion Diagnostics for <i>BRAF</i> V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Studyhttps://www.pharmaradar360.com/article/supplementary-table-s11-from-clinical-validation-of-tissue-and-liquid-companion-1bfb97cafa938bd0Pharma Surgeen2026-07-29T00:00:00.000ZSupplementary Table S11 from Clinical Validation of Tissue and Liquid Companion Diagnostics for <i>BRAF</i> V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Studyhttps://www.pharmaradar360.com/article/supplementary-table-s3-from-clinical-validation-of-tissue-and-liquid-companion-d-896a2aff2f84e080Pharma Surgeen2026-07-29T00:00:00.000ZSupplementary Table S3 from Clinical Validation of Tissue and Liquid Companion Diagnostics for <i>BRAF</i> V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Studyhttps://www.pharmaradar360.com/article/supplementary-table-s9-from-clinical-validation-of-tissue-and-liquid-companion-d-dcf0f5a81cc9211dPharma Surgeen2026-07-29T00:00:00.000ZSupplementary Table S9 from Clinical Validation of Tissue and Liquid Companion Diagnostics for <i>BRAF</i> V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Studyhttps://www.pharmaradar360.com/article/table-3-from-clinical-validation-of-tissue-and-liquid-companion-diagnostics-for-36683b6cdbb57f29Pharma Surgeen2026-07-29T00:00:00.000ZTable 3 from Clinical Validation of Tissue and Liquid Companion Diagnostics for <i>BRAF</i> V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Studyhttps://www.pharmaradar360.com/article/bowel-dysfunction-lars-and-quality-of-life-after-chemoradiotherapy-and-local-exc-995f71ac855d7c2bPharma Surgeen2026-07-29T00:00:00.000ZBowel dysfunction (LARS) and quality of life after chemoradiotherapy and local excision versus total mesorectal excision in T2–T3ab, N0, M0 rectal cancer: the TAUTEM randomized clinical trialhttps://www.pharmaradar360.com/article/hepatic-responses-as-potential-biomarkers-of-idiosyncratic-drug-reaction-risk-e4c2c0e44937ba49Pharma Surgeen2026-07-29T00:00:00.000ZHepatic Responses as Potential Biomarkers of Idiosyncratic Drug Reaction Riskhttps://www.pharmaradar360.com/article/clinical-justification-for-osteoporosis-investigation-transitioning-from-opportu-5ac54108315832c5Pharma Surgeen2026-07-29T00:00:00.000ZClinical justification for osteoporosis investigation: transitioning from opportunistic to diagnostic referrals from alternative forms of imaginghttps://www.pharmaradar360.com/article/mechanisms-of-change-in-mobile-app-delivered-acceptance-and-commitment-therapy-f-ec48b5972757603ePharma Surgeen2026-07-29T00:00:00.000ZMechanisms of change in mobile app-delivered acceptance and commitment therapy for posttraumatic stress disorder in China: a secondary analysis of a randomized controlled trialhttps://www.pharmaradar360.com/article/efficacy-of-targeted-neuromodulation-treatments-a-clinical-report-90f1b12c9a93676fPharma Surgeen2026-07-29T00:00:00.000ZEfficacy of targeted neuromodulation treatments: a clinical reporthttps://www.pharmaradar360.com/article/diagnosis-of-traumatic-diaphragmatic-injury-remains-a-clinical-challenge-brief-r-2513aadc6f7ce58bPharma Surgeen2026-07-29T00:00:00.000ZDiagnosis of traumatic diaphragmatic injury remains a clinical challenge – Brief reporthttps://www.pharmaradar360.com/article/lactate-aars1-mediated-h3k18la-in-the-modulation-of-acsl4-transcription-to-trigg-7542e503cc53a5fbPharma Surgeen2026-07-29T00:00:00.000ZLactate/AARS1-mediated H3K18la in the modulation of ACSL4 transcription to trigger ferroptosis in myocardial ischemia reperfusionhttps://www.pharmaradar360.com/article/clinical-and-biomechanical-recovery-trajectories-during-anti-gravity-treadmill-a-0f7d71ffe0753363Pharma Surgeen2026-07-29T00:00:00.000ZClinical and biomechanical recovery trajectories during anti-gravity treadmill-assisted rehabilitation after complex lower-limb articular fractures: a prospective pilot cohort studyhttps://www.pharmaradar360.com/article/cognitive-behavioral-therapy-as-an-adjunct-to-physical-management-of-chronic-pai-022827b31be28764Pharma Surgeen2026-07-29T00:00:00.000ZCognitive-behavioral therapy as an adjunct to physical management of chronic painful temporomandibular disorders: A DC/TMD Axis II guided randomized controlled trialhttps://www.pharmaradar360.com/article/effects-of-psychosocial-stress-on-opioid-self-administration-in-healthy-particip-35177d0e89ab543ePharma Surgeen2026-07-29T00:00:00.000ZEffects of psychosocial stress on opioid self-administration in healthy participants: a randomized, placebo-controlled crossover trialhttps://www.pharmaradar360.com/article/development-and-pilot-evaluation-of-an-electronic-trigger-based-surveillance-mod-4c8e0723ba8f1174Pharma Surgeen2026-07-29T00:00:00.000ZDevelopment and pilot evaluation of an electronic trigger-based surveillance model for sedative-hypnotic drug misuse in a tertiary hospitalhttps://www.pharmaradar360.com/article/invasive-mold-infection-in-pediatric-acute-lymphoblastic-leukemia-a-detailed-ana-374757c6b434d9c9Pharma Surgeen2026-07-29T00:00:00.000ZInvasive mold infection in pediatric acute lymphoblastic leukemia—a detailed analysis of the clinical trial AIEOP-BFM ALL2009https://www.pharmaradar360.com/article/effect-of-ocean-sounds-played-during-retinopathy-of-prematurity-examinations-on-32eb7e236c69efb6Pharma Surgeen2026-07-29T00:00:00.000ZEffect of ocean sounds played during retinopathy of prematurity examinations on physiology, pain, and comfort levels: a randomized controlled trialhttps://www.pharmaradar360.com/article/to-help-children-with-rare-diseases-we-must-solve-drug-delivery-f975e8b4eec1cf81Pharma Surgeen2026-07-29T00:00:00.000ZTo help children with rare diseases, we must solve drug deliveryhttps://www.pharmaradar360.com/article/a-randomised-controlled-trial-to-study-the-use-of-large-language-models-prompt-e-67cb4825988cf2b7Pharma Surgeen2026-07-29T00:00:00.000ZA Randomised Controlled Trial to Study the Use of Large Language Models Prompt Engineered with Socratic Methods on the Impact of Medical Students’ Learninghttps://www.pharmaradar360.com/article/signals-of-venous-thromboembolism-risk-from-drug-drug-interactions-involving-ben-36c9eac2f2bfb402Pharma Surgeen2026-07-29T00:00:00.000ZSignals of Venous Thromboembolism Risk from Drug–Drug Interactions Involving Benzodiazepines and Other Sedative Hypnotics: Self-Controlled Case Series Analyseshttps://www.pharmaradar360.com/article/assessment-of-prevalence-and-clinical-profile-and-risk-factors-for-pregnancy-rel-749e12b3f156111cPharma Surgeen2026-07-29T00:00:00.000ZAssessment of Prevalence and Clinical Profile and Risk Factors for Pregnancy-Related Acute Kidney Injury in a Tertiary Care Hospital in Indiahttps://www.pharmaradar360.com/article/erap1-rs27038-polymorphism-and-il-17a-in-radiographic-axial-spondyloarthritis-a-e6433978a4bb3c3bPharma Surgeen2026-07-29T00:00:00.000ZERAP1 rs27038 Polymorphism and IL-17A in Radiographic Axial Spondyloarthritis: A South Indian Case–Control Studyhttps://www.pharmaradar360.com/article/sexual-myths-and-self-consciousness-in-women-a-randomized-controlled-trial-on-th-99bee67efeea80b6Pharma Surgeen2026-07-29T00:00:00.000ZSexual Myths and Self-Consciousness in Women: A Randomized Controlled Trial on the Power of Educationhttps://www.pharmaradar360.com/article/comparison-of-accelerated-mri-protocol-approaches-for-clinical-assessment-of-the-0cc4ec9a027eb9c9Pharma Surgeen2026-07-29T00:00:00.000ZComparison of accelerated MRI protocol approaches for clinical assessment of the kneehttps://www.pharmaradar360.com/article/comparative-clinical-and-molecular-epidemiology-of-norovirus-in-hospitalized-gas-ea5324f6962c6f22Pharma Surgeen2026-07-29T00:00:00.000ZComparative Clinical and Molecular Epidemiology of Norovirus in Hospitalized Gastroenteritis Cases, Western India (2013‐2023)https://www.pharmaradar360.com/article/engineering-extracellular-vesicles-strategies-for-functional-modification-and-cl-51b52d6bdfbbe28aPharma Surgeen2026-07-29T00:00:00.000ZEngineering Extracellular Vesicles: Strategies for Functional Modification and Clinical Translationhttps://www.pharmaradar360.com/article/intelligent-automation-improved-efficiency-in-pharmacovigilance-safety-signal-as-6c29b1165f601d81Pharma Surgeen2026-07-29T00:00:00.000ZIntelligent Automation Improved Efficiency in Pharmacovigilance Safety Signal Assessmenthttps://www.pharmaradar360.com/article/comment-on-association-of-ticagrelor-metabolic-snps-with-adverse-drug-reactions-d3b05cbb6cc6edbaPharma Surgeen2026-07-29T00:00:00.000ZComment on “Association of Ticagrelor Metabolic SNPs With Adverse Drug Reactions in Patients With Acute Coronary Syndrome”https://www.pharmaradar360.com/article/in-adults-with-low-back-pain-with-modic-type-1-changes-and-disc-herniation-on-ma-a8ad1d42ce0e3e83Pharma Surgeen2026-07-29T00:00:00.000ZIn adults with low back pain with Modic type 1 changes and disc herniation on magnetic resonance imaging (MRI), what are the benefits and harms of antibiotic therapy compared with placebo?https://www.pharmaradar360.com/article/pharmacometric-evaluation-of-pre-referral-rectal-artesunate-in-children-with-sev-0fec6df4bc640627Pharma Surgeen2026-07-29T00:00:00.000ZPharmacometric evaluation of pre‐referral rectal artesunate in children with severe malariahttps://www.pharmaradar360.com/article/nct07735065-tumor-specific-t-cells-cctl-gl01-for-advanced-gastrointestinal-cance-7c5be145f71506d3Pharma Surgeen2026-07-29T00:00:00.000ZNCT07735065: Tumor-Specific T-Cells (cCTL:GL01) for Advanced Gastrointestinal Cancerhttps://www.pharmaradar360.com/article/nct07734727-adaptation-and-testing-of-a-novel-text-based-tobacco-cessation-and-e-1a37f3a316a02ca7Pharma Surgeen2026-07-29T00:00:00.000ZNCT07734727: Adaptation and Testing of a Novel Text-based Tobacco Cessation and Education Intervention in Kenyan Emergency Department Patientshttps://www.pharmaradar360.com/article/nct07734506-relationship-between-ultrasonographic-quadriceps-muscle-thickness-an-8fae53fc932b91f8Pharma Surgeen2026-07-29T00:00:00.000ZNCT07734506: RELATIONSHIP BETWEEN ULTRASONOGRAPHIC QUADRICEPS MUSCLE THICKNESS AND SARCOPENIA MARKERS (HANDGRIP STRENGTH, SARC-F) AND KINESIOPHOBIA IN STROKE PATIENTShttps://www.pharmaradar360.com/article/nct07734389-genetic-assessment-of-breast-cancer-risk-in-women-in-the-dora-progra-5d3389d298effd7dPharma Surgeen2026-07-29T00:00:00.000ZNCT07734389: Genetic Assessment of Breast Cancer Risk in Women in the DORA Programmehttps://www.pharmaradar360.com/article/nct07734285-detection-of-cardiac-amyloidosis-using-right-ventricular-sensing-amp-9ca9c588e7fbe226Pharma Surgeen2026-07-29T00:00:00.000ZNCT07734285: Detection of Cardiac Amyloidosis Using Right Ventricular Sensing Amplitude in Patients With Left Ventricular Hypertrophyhttps://www.pharmaradar360.com/article/nct07733882-study-on-clinical-and-pathological-features-of-primary-biliary-chola-f2543ac87df43590Pharma Surgeen2026-07-29T00:00:00.000ZNCT07733882: Study on Clinical and Pathological Features of Primary Biliary Cholangitis and Risk Factors Related to Disease Progressionhttps://www.pharmaradar360.com/article/nct07733583-pelvic-floor-physical-therapy-and-exercise-for-women-with-endometrio-70c02a760181efd1Pharma Surgeen2026-07-29T00:00:00.000ZNCT07733583: Pelvic Floor Physical Therapy and Exercise for Women With Endometriosis and Chronic Pelvic Painhttps://www.pharmaradar360.com/article/nct07733388-the-effectiveness-of-home-based-circuit-training-on-eye-pressure-and-f64a701c2831cb2bPharma Surgeen2026-07-29T00:00:00.000ZNCT07733388: The Effectiveness Of Home-Based Circuit Training On Eye Pressure And Eye Nerve Structures In Patients With Glaucomahttps://www.pharmaradar360.com/article/nct07733323-respiratory-physiotherapy-for-patients-with-bronchiectasis-bcac846311f3b105Pharma Surgeen2026-07-29T00:00:00.000ZNCT07733323: Respiratory Physiotherapy for Patients With Bronchiectasishttps://www.pharmaradar360.com/article/nct07733310-augmented-depression-therapy-adept-case-series-dc3341fc3a2e72edPharma Surgeen2026-07-29T00:00:00.000ZNCT07733310: Augmented Depression Therapy (ADepT) Case Serieshttps://www.pharmaradar360.com/article/nct07733141-mindfulness-intervention-to-reduce-patient-reported-symptoms-in-pati-f9f3ccf64a3478fdPharma Surgeen2026-07-29T00:00:00.000ZNCT07733141: Mindfulness Intervention to Reduce Patient Reported Symptoms in Patients With Chronic Graft-Versus-Host Diseasehttps://www.pharmaradar360.com/article/nct07732790-clinical-evaluation-of-two-fissure-sealants-resin-based-versus-giome-f90f5e548308c094Pharma Surgeen2026-07-29T00:00:00.000ZNCT07732790: Clinical Evaluation of Two Fissure Sealants (Resin Based Versus Giomer Fissure Sealants) on Molar Incisor Hypominerlisation Affected Permanent Molars (RCT)https://www.pharmaradar360.com/article/nct07732712-isa-vrdlite-for-of-frail-and-or-much-older-patients-with-high-risk-n-2d934dabe0e3c3b4Pharma Surgeen2026-07-29T00:00:00.000ZNCT07732712: Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cellshttps://www.pharmaradar360.com/article/nct07728773-a-stepped-intervention-for-coping-with-dyspnea-in-patients-with-lung-4fc3f9a6bc734b40Pharma Surgeen2026-07-29T00:00:00.000ZNCT07728773: A Stepped Intervention for Coping With Dyspnea in Patients With Lung Cancer-Phase A (Open Pilot)https://www.pharmaradar360.com/article/nct07723495-symptom-management-to-improve-completion-of-patient-reported-outcome-57cbc7b487e094ecPharma Surgeen2026-07-29T00:00:00.000ZNCT07723495: Symptom Management to Improve Completion of Patient-reported Outcome Measureshttps://www.pharmaradar360.com/article/nct07722390-minimally-invasive-non-surgical-treatment-using-injectable-platelet-fc9068cee30257caPharma Surgeen2026-07-29T00:00:00.000ZNCT07722390: Minimally Invasive Non Surgical Treatment Using Injectable Platelet Concentrate in Treatment of Deep Pockets.https://www.pharmaradar360.com/article/nct07668115-gamifying-hand-therapy-development-of-a-mixed-reality-rhythm-game-to-c8d5f3faf811a27fPharma Surgeen2026-07-29T00:00:00.000ZNCT07668115: Gamifying Hand Therapy: Development of a Mixed Reality Rhythm Game to Reduce Pain and Improve Motivationhttps://www.pharmaradar360.com/article/nct07635186-a-study-to-evaluate-ahb-137-injection-in-treatment-naive-participant-d409dd3edd766012Pharma Surgeen2026-07-29T00:00:00.000ZNCT07635186: A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis Bhttps://www.pharmaradar360.com/article/nct07613099-fibrotic-disease-activity-in-cardiopulmonary-disorders-using-18f-fib-d3d2836ef9a19c9fPharma Surgeen2026-07-29T00:00:00.000ZNCT07613099: Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaginghttps://www.pharmaradar360.com/article/nct07600788-a-clinical-study-evaluating-the-pharmacokinetic-characteristics-and-45c5263b391e956aPharma Surgeen2026-07-29T00:00:00.000ZNCT07600788: A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function.https://www.pharmaradar360.com/article/nct07594652-medication-treatment-of-adhd-in-pediatric-epilepsy-833b4698a6ff1dafPharma Surgeen2026-07-29T00:00:00.000ZNCT07594652: Medication Treatment of ADHD in Pediatric Epilepsyhttps://www.pharmaradar360.com/article/nct07567599-deep-brain-stimulation-in-parkinson-s-disease-motor-and-functional-o-c311a4436f5d10b8Pharma Surgeen2026-07-29T00:00:00.000ZNCT07567599: Deep Brain Stimulation in Parkinson's Disease: Motor and Functional Outcomeshttps://www.pharmaradar360.com/article/nct07305818-nexus-study-a-study-to-test-single-and-multiple-doses-of-mer511-give-c5085944d80baa43Pharma Surgeen2026-07-29T00:00:00.000ZNCT07305818: NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Diseasehttps://www.pharmaradar360.com/article/nct07169630-pet-imaging-of-phosphodiesterase-4-pde4-in-volunteers-with-alzheimer-ad9bf3a66aac9969Pharma Surgeen2026-07-29T00:00:00.000ZNCT07169630: PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)https://www.pharmaradar360.com/article/nct07111065-fast-for-dm-fatty-acid-supplementation-trial-fast-for-dermatomyositi-ed2b3f59cab40468Pharma Surgeen2026-07-29T00:00:00.000ZNCT07111065: FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)https://www.pharmaradar360.com/article/nct07084012-a-phase-iia-clinical-trial-to-evaluate-the-efficacy-and-safety-of-in-29bed79991fd7d1dPharma Surgeen2026-07-29T00:00:00.000ZNCT07084012: A Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Infusion of hUC-MSCs in Patients With AIShttps://www.pharmaradar360.com/article/nct07015242-a-study-of-the-efficacy-and-safety-of-lisocabtagene-maraleucel-liso-6604f7522a5732abPharma Surgeen2026-07-29T00:00:00.000ZNCT07015242: A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphomahttps://www.pharmaradar360.com/article/nct07005752-a-study-to-evaluate-the-efficacy-and-safety-of-cnu-capsule-750-mg-in-49d8354c4df59e7fPharma Surgeen2026-07-29T00:00:00.000ZNCT07005752: A Study to Evaluate the Efficacy and Safety of CnU Capsule 750 mg in Patients With Cholesterol Gallstones(GB Stones).https://www.pharmaradar360.com/article/nct06975865-the-efficacy-and-safety-of-rilzabrutinib-in-participants-aged-10-to-46aa95cc12af7b93Pharma Surgeen2026-07-29T00:00:00.000ZNCT06975865: The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Diseasehttps://www.pharmaradar360.com/article/nct06923280-sequential-peg-ifn-for-hbv-after-ending-rna-targeted-regimens-bf3f534fb1b20009Pharma Surgeen2026-07-29T00:00:00.000ZNCT06923280: Sequential PEG-IFN for HBV After Ending RNA-targeted Regimenshttps://www.pharmaradar360.com/article/nct06679751-infectious-disease-id-testing-outreach-in-carceral-hubs-b458d0cfbf0cdd3dPharma Surgeen2026-07-29T00:00:00.000ZNCT06679751: Infectious Disease (ID) Testing OUtreach in Carceral Hubshttps://www.pharmaradar360.com/article/nct06661200-exploratory-study-of-the-diagnostic-potential-of-an-innovative-thora-dd798ea3cd2fa91bPharma Surgeen2026-07-29T00:00:00.000ZNCT06661200: Exploratory Study of the Diagnostic Potential of an Innovative Thoracic Vibration Analysis Techniquehttps://www.pharmaradar360.com/article/nct06562192-phase-i-study-of-177lu-lu-nns309-in-patients-with-pancreatic-lung-br-502e809bd5037eb1Pharma Surgeen2026-07-29T00:00:00.000ZNCT06562192: Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancershttps://www.pharmaradar360.com/article/nct06487481-study-of-preoperative-radiation-therapy-in-participants-with-resecta-fc044139700317d0Pharma Surgeen2026-07-29T00:00:00.000ZNCT06487481: Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinomahttps://www.pharmaradar360.com/article/nct06486441-study-of-sacituzumab-govitecan-versus-treatment-of-physician-s-choic-01421e623f163c76Pharma Surgeen2026-07-29T00:00:00.000ZNCT06486441: Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)https://www.pharmaradar360.com/article/nct06079671-study-of-volrustomig-in-women-with-high-risk-locally-advanced-cervic-6fc2a99bc9910df2Pharma Surgeen2026-07-29T00:00:00.000ZNCT06079671: Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)https://www.pharmaradar360.com/article/nct05896852-healthy-lifestyles-a-home-based-physical-activity-intervention-in-pe-125c00ede7e36abdPharma Surgeen2026-07-29T00:00:00.000ZNCT05896852: Healthy Lifestyles: A Home Based Physical Activity Intervention in Persons Living With HIVhttps://www.pharmaradar360.com/article/nct05856994-clinical-assessment-of-protopic-ointment-in-deep-partial-thickness-b-ff15c4cea27f142fPharma Surgeen2026-07-29T00:00:00.000ZNCT05856994: Clinical Assessment of Protopic® Ointment in Deep Partial-Thickness Burnshttps://www.pharmaradar360.com/article/nct05652504-safety-evaluation-of-pfspz-vaccine-in-pregnant-women-in-mali-malvip1-42c9082b83410242Pharma Surgeen2026-07-29T00:00:00.000ZNCT05652504: Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)https://www.pharmaradar360.com/article/nct05538130-a-study-to-learn-about-the-study-medicine-called-pf-07799544-as-mono-3bee4b1b5cf2a2c3Pharma Surgeen2026-07-29T00:00:00.000ZNCT05538130: A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumorshttps://www.pharmaradar360.com/article/nct05419492-a-clinical-study-to-evaluate-the-safety-and-efficacy-of-etx101-in-in-f1a9086daa708a8aPharma Surgeen2026-07-29T00:00:00.000ZNCT05419492: A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndromehttps://www.pharmaradar360.com/article/nct05365659-iks03-in-patients-with-advanced-b-cell-non-hodgkin-lymphomas-bc88a351e3f9141dPharma Surgeen2026-07-29T00:00:00.000ZNCT05365659: IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomashttps://www.pharmaradar360.com/article/nct05144789-personalized-therapeutic-neuromodulation-for-anhedonic-depression-6b5a8131b1328a39Pharma Surgeen2026-07-29T00:00:00.000ZNCT05144789: Personalized Therapeutic Neuromodulation for Anhedonic Depressionhttps://www.pharmaradar360.com/article/nct05045950-optimizing-neurocognition-with-whole-brain-radiation-therapy-wbrt-us-6eacc09afd1b07c9Pharma Surgeen2026-07-29T00:00:00.000ZNCT05045950: Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Techniquehttps://www.pharmaradar360.com/article/nct04994132-a-study-to-compare-early-use-of-vinorelbine-and-maintenance-therapy-f79a7c3936b9384dPharma Surgeen2026-07-29T00:00:00.000ZNCT04994132: A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcomahttps://www.pharmaradar360.com/article/nct04987060-intrastromal-fresh-human-corneal-lenticule-implantation-using-smile-f90b8fa71816e00fPharma Surgeen2026-07-29T00:00:00.000ZNCT04987060: Intrastromal Fresh Human Corneal Lenticule Implantation Using Smile Surgery for Treatment of Irregular Corneal Astigmatism After Penetrating Keratoplasty (New Approach)https://www.pharmaradar360.com/article/nct04808427-pilot-study-to-investigate-magnetic-resonance-mr-image-guided-focal-b4623e9007f72207Pharma Surgeen2026-07-29T00:00:00.000ZNCT04808427: Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancerhttps://www.pharmaradar360.com/article/nct04712643-a-study-of-tace-combined-with-atezolizumab-plus-bevacizumab-or-tace-e9d05191c1dcefbePharma Surgeen2026-07-29T00:00:00.000ZNCT04712643: A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionmahttps://www.pharmaradar360.com/article/nct04712318-treatment-of-residual-refraction-errors-6-months-after-trifocal-iol-94c0caacedcb0989Pharma Surgeen2026-07-29T00:00:00.000ZNCT04712318: Treatment of Residual Refraction Errors 6 Months After Trifocal IOL Implantation With Relex-Smilehttps://www.pharmaradar360.com/article/nct04693663-treatment-of-residual-myopic-refraction-after-6-months-on-pseudophak-a4b4662bc9b877bdPharma Surgeen2026-07-29T00:00:00.000ZNCT04693663: Treatment of Residual Myopic Refraction After 6 Months on Pseudophakic Patients Using Relex-Smilehttps://www.pharmaradar360.com/article/nct04649242-randomized-study-in-children-and-adolescents-with-migraine-acute-tre-736a6a2704f27e77Pharma Surgeen2026-07-29T00:00:00.000ZNCT04649242: Randomized Study in Children and Adolescents With Migraine: Acute Treatmenthttps://www.pharmaradar360.com/article/nct04609046-testing-the-addition-of-lenalidomide-and-nivolumab-to-the-usual-trea-7f50f948c51ec8edPharma Surgeen2026-07-29T00:00:00.000ZNCT04609046: Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphomahttps://www.pharmaradar360.com/article/nct04588922-study-of-sls009-formerly-gfh009-a-potent-highly-selective-cdk9-inhib-ffe874879ffb4235Pharma Surgeen2026-07-29T00:00:00.000ZNCT04588922: Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AMLhttps://www.pharmaradar360.com/article/nct04323774-intervention-for-adolescents-and-young-adults-ayas-with-cancer-risk-8164f1c66504c378Pharma Surgeen2026-07-29T00:00:00.000ZNCT04323774: Intervention For Adolescents and Young Adults (AYAs) With Cancer Risk Syndromeshttps://www.pharmaradar360.com/article/nct03005418-humacyte-acellular-tissue-engineered-vessel-atev-in-patients-with-va-f4361e70c97ab02cPharma Surgeen2026-07-29T00:00:00.000ZNCT03005418: Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular Traumahttps://www.pharmaradar360.com/article/nct02003222-combination-chemotherapy-with-or-without-blinatumomab-in-treating-pa-489f33c4c086296dPharma Surgeen2026-07-29T00:00:00.000ZNCT02003222: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemiahttps://www.pharmaradar360.com/article/nct00644228-lenalidomide-and-dexamethasone-with-or-without-bortezomib-in-treatin-bccb6c8deb96ee82Pharma Surgeen2026-07-29T00:00:00.000ZNCT00644228: Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myelomahttps://www.pharmaradar360.com/article/nct00593840-phase-ii-trial-evaluating-elimination-of-radiation-therapy-1f8727b1b1cb6922Pharma Surgeen2026-07-29T00:00:00.000ZNCT00593840: Phase II Trial Evaluating Elimination of Radiation Therapyhttps://www.pharmaradar360.com/article/nct00458536-vaccination-of-patients-with-renal-cell-cancer-with-dendritic-cell-t-f889f6bb6449bbcePharma Surgeen2026-07-29T00:00:00.000ZNCT00458536: Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSFhttps://www.pharmaradar360.com/article/nct00341276-esophageal-cancer-genetics-studies-4c16dbff9d3f452bPharma Surgeen2026-07-29T00:00:00.000ZNCT00341276: Esophageal Cancer Genetics Studieshttps://www.pharmaradar360.com/article/marsha-blackburn-threatens-lawsuit-over-dark-money-pac-ad-43ad49d031107504Pharma Surgeen2026-07-28T23:54:08.000ZMarsha Blackburn threatens lawsuit over dark money PAC adhttps://www.pharmaradar360.com/article/no-a-judge-did-not-rule-abortion-pills-are-safe-c82921f2e691141fPharma Surgeen2026-07-28T23:45:00.000ZNo a Judge Did Not Rule Abortion Pills are Safehttps://www.pharmaradar360.com/article/bb-biotech-ag-2026-q2-results-earnings-call-presentation-otcmkts-bbagf-2026-07-2-5edd656ea9049366Pharma Surgeen2026-07-28T23:07:11.000ZBB Biotech AG 2026 Q2 - Results - Earnings Call Presentation (OTCMKTS:BBAGF) 2026-07-28https://www.pharmaradar360.com/article/psm-submits-comment-supporting-the-continued-exclusion-of-glp-1s-from-the-503b-b-644a2837edfbcf8bPharma Surgeen2026-07-28T22:59:35.000ZPSM submits comment supporting the continued exclusion of GLP-1s from the 503B Bulks Listhttps://www.pharmaradar360.com/article/arkansas-suspends-enforcement-of-law-limiting-pharmaceutical-distribution-bde47dd0965c25b2Pharma Surgeen2026-07-28T22:57:00.000ZArkansas suspends enforcement of law limiting pharmaceutical distributionhttps://www.pharmaradar360.com/article/portage-biotech-alp-stock-trends-and-sentiment-2026-alp-30e8051ee934e3faPharma Surgeen2026-07-28T22:51:23.000ZPortage Biotech (ALP) Stock Trends and Sentiment 2026 $ALPhttps://www.pharmaradar360.com/article/black-bird-biotech-inc-revenue-breakdown-otc-bbbt-baecba98ea07f053Pharma Surgeen2026-07-28T22:27:13.000ZBLACK BIRD BIOTECH INC Revenue Breakdown – OTC:BBBThttps://www.pharmaradar360.com/article/fda-official-insists-u-s-food-supply-is-safe-as-cyclosporiasis-cases-hit-11-000-e2c9d6210f4e61f3Pharma Surgeen2026-07-28T22:10:00.000ZFDA official insists ‘U.S. food supply is safe’ as cyclosporiasis cases hit 11,000https://www.pharmaradar360.com/article/kobayashi-pharmaceutical-co-ltd-revenue-breakdown-tradegate-koy-7956a715383ca6a9Pharma Surgeen2026-07-28T21:55:26.000ZKobayashi Pharmaceutical Co., Ltd. Revenue Breakdown – TRADEGATE:KOY